Hans J. Hammers, MD, PhD
Immunotherapy combinations continue to demonstrate improved response rates for patients with renal cell carcinoma (RCC). Frontline therapy with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with standard sunitinib (Sutent) for patients with metastatic disease, according to data from the CheckMate-214 study.
In an interview with OncLive at the 35th Annual Chemotherapy Foundation Symposium, Hammers, who is co-leader of the Kidney Cancer Program at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discussed the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with RCC.
OncLive: Please provide an overview of your presentation at this meeting.
: I discussed immunotherapy combinations. It is an exciting time because it is expected that immunotherapy combinations are going to supplant first-line tyrosine kinase inhibitor (TKI) therapy. We have had sunitinib for more than a decade. Just recently, one of the pivotal trials was positive and beat sunitinib in response rate and OS. The PFS in the intermediate- and poor-risk population was 75% in all patients with kidney cancer.
... to read the full story